French consensus: Pharmacoresistant restless legs syndrome

Area of Science:

• Neurology
• Sleep Medicine
• Pharmacology

Background:

• Restless Legs Syndrome (RLS), also known as Willis-Ekbom disease, is commonly treated with dopaminergic agonists, α2δ ligands, and opioids.
• Despite initial efficacy, some RLS patients experience symptom exacerbation without meeting augmentation criteria, leading to 'drug-resistant' RLS.

Purpose of the Study:

• To propose a diagnostic and therapeutic strategy for drug-resistant RLS.
• To address the lack of specific French recommendations for managing this challenging RLS subtype.
• To improve patient care by identifying and treating organic, psychiatric, or iatrogenic causes of drug resistance.

Main Methods:

• Recommended work-up includes video-polysomnography and biological evaluation (iron status, complete blood count, C-reactive protein).
• Treatment strategies are tailored based on comorbidities.
• Diagnostic and therapeutic approach for drug-resistant RLS.

Main Results:

• Comorbidity-dependent treatment recommendations are provided.
• Dopaminergic agonists are suggested for depression or periodic leg movements.
• α2δ ligands are recommended for insomnia, pain, or anxiety, with opioids used as needed.

Conclusions:

• A systematic diagnostic and therapeutic strategy is crucial for managing drug-resistant RLS.
• Addressing underlying causes and comorbidities is key to effective treatment.
• Strong opioids are suggested for multiresistant RLS cases.